Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease


Thomas U Ahearn, Sam Peisch, Andreas Pettersson, Ericka M Ebot, Cindy Ke Zhou, Rebecca E Graff, Jennifer A Sinnott, Ladan Fazli, Gregory L Judson, Tarek A Bismar, Jennifer R Rider, Travis Gerke, June M Chan, Michelangelo Fiorentino, Richard Flavin, Howard D Sesso, Stephen Finn, Edward L Giovannucci, Martin Gleave, Massimo Loda, Zhe Li, Michael Pollak, and Lorelei A Mucci. 2018. “Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.” Carcinogenesis, 39, 12, Pp. 1431-1437.


Circulating insulin-like growth factor-1 (IGF-1) is consistently associated with prostate cancer risk. IGF-1 binds to IGF-1 receptor (IGF1R) and insulin receptor (IR), activating cancer hallmark pathways. Experimental evidence suggests that TMPRSS2:ERG may interact with IGF/insulin signaling to influence progression. We investigated IGF1R and IR expression and its association with lethal prostate cancer among 769 men. Protein expression of IGF1R, IR and ERG (i.e. a surrogate of ERG fusion genes) were assayed by immunohistochemistry. Cox models estimated hazard ratios (HR) and 95% confidence intervals (CI) adjusted for clinical characteristics. Among patients, 29% had strong tumor IGF1R expression and 10% had strong IR expression. During a mean follow-up of 13.2 years through 2012, 80 men (11%) developed lethal disease. Tumors with strong IGF1R or IR expression showed increased cell proliferation, decreased apoptosis and a higher prevalence of ERG. In multivariable models, strong IGF1R was associated with a borderline increased risk of lethal prostate cancer (HR 1.7; 95% CI 0.9-3.1). The association appeared greater in ERG-positive tumors (HR 2.8; 95% CI 0.9-8.4) than in ERG-negative tumors (HR 1.3; 95% CI 0.6-3.0, p-heterogeneity 0.08). There was no association between IR and lethal prostate cancer (HR 0.8; 95% CI 0.4-1.9). These results suggest that tumor IGF1R expression may play a role in prostate cancer progression to a lethal phenotype and that ERG-positive tumors may be more sensitive to IGF signaling. These data may improve our understanding of IGF signaling in prostate cancer and suggest therapeutic options for disease subtypes.